CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination

Journal of Immunology

Volumn 185, Issue 11, 2010, Pages 6706-6718

  Miguel, Rodolfo D Vicetti ^a,b   Cherpes, Thomas L ^c   Watson, Leah J ^d,e   McKenna, Kyle C ^b  

^a Graduate Program in Immunology   (United States)

^b Department of Ophthalmology ^*  (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL ISOLATION; CONCENTRATION (PARAMETERS); CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; EX VIVO STUDY; EYE TUMOR; FEMALE; IN VITRO STUDY; MACROPHAGE; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; SUPPRESSOR CELL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; CELL LINE, TUMOR; CYTOKINES; CYTOPLASMIC GRANULES; EXOCYTOSIS; EYE NEOPLASMS; FEMALE; LEUKEMIA, EXPERIMENTAL; LYMPHOMA, T-CELL; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; NITRIC OXIDE; SKIN NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78650648668     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903411     Document Type: Article

References (53)

1. Streilein, J. W. 2003. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol. 3:879-889.
2. Niederkorn, J. Y. 2006. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat. Immunol. 7:354-359.
3. Niederkorn, J. Y. 2009. Immune escape mechanisms of intraocular tumors. Prog. Retin. Eye Res. 28:329-347.
4. Niederkorn, J. Y., J. W. Streilein, and J. A. Shadduck. 1981. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest. Ophthalmol. Vis. Sci. 20:355-363.
5. McKenna, K. C., and J. A. Kapp. 2006. Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye. J. Immunol. 177:1599-1608.
6. Niederkorn, J. Y., and J. W. Streilein. 1983. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses. J. Immunol. 131:2670-2674.
7. Ksander, B. R., and J. W. Streilein. 1989. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors. Invest. Ophthalmol. Vis. Sci. 30:323-329.
8. Niederkorn, J. Y., and J. W. Streilein. 1983. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge. J. Immunol. 131:2587-2594.
9. Durie, F. H., A. M. Campbell, W. R. Lee, and B. E. Damato. 1990. Analysis of lymphocytic infiltration in uveal melanoma. Invest. Ophthalmol. Vis. Sci. 31:2106-2110.
10. Meecham, W. J., D. H. Char, and S. Kaleta-Michaels. 1992. Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res. 24:20-26.
11. Chen, P. W., T. Uno, and B. R. Ksander. 2006. Tumor escape mutants develop within an immune-privileged environment in the absence of T cell selection. J. Immunol. 177:162-168.
12. Hallermalm, K., K. Seki, A. de Geer, B. Motyka, R. C. Bleackley, M. J. Jager, C. J. Froelich, R. Kiessling, V. Levitsky, and J. Levitskaya. 2008. Modulation of the tumor cell phenotype by IFN-gamma results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes. J. Immunol. 180:3766-3774.
13. Griffith, T. S., T. Brunner, S. M. Fletcher, D. R. Green, and T. A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192.
14. Lee, H. O., J. M. Herndon, R. Barreiro, T. S. Griffith, and T. A. Ferguson. 2002. TRAIL: a mechanism of tumor surveillance in an immune privileged site. J. Immunol. 169:4739-4744.
15. Hori, J., M. Wang, M. Miyashita, K. Tanemoto, H. Takahashi, T. Takemori, K. Okumura, H. Yagita, and M. Azuma. 2006. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts. J. Immunol. 177:5928-5935.
16. Shrikant, P., and M. F. Mescher. 1999. Control of syngeneic tumor growth by activation of CD8+ T cells: efficacy is limited by migration away from the site and induction of nonresponsiveness. J. Immunol. 162:2858-2866.
17. Ksander, B. R., D. C. Geer, P. W. Chen, M. L. Salgaller, P. Rubsamen, and T. G. Murray. 1998. Uveal melanomas contain antigenically specific and nonspecific infiltrating lymphocytes. Curr. Eye Res. 17:165-173.
18. + granulocytes increase in the blood of patients with uveal melanoma. Invest. Ophthalmol. Vis. Sci. 50:4295-4303.
19. Staibano, S., M. Mascolo, F. Tranfa, G. Salvatore, C. Mignogna, P. Bufo, L. Nugnes, G. Bonavolontà, and G. de Rosa. 2006. Tumor infiltrating lymphocytes in uveal melanoma: a link with clinical behavior? Int. J. Immunopathol. Pharmacol. 19:171-179.
20. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
21. Mäkitie, T., P. Summanen, A. Tarkkanen, and T. Kivelä. 2001. Tumor-infiltrating macrophages (CD68 (+) cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 42:1414-1421.
22. Hollenbaugh, J. A., and R. W. Dutton. 2006. IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J. Immunol. 177:3004-3011.
23. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17-27.
24. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777-785.
25. Zhang, B., N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y. X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. 2007. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204:49-55.
26. Darrah, P. A., D. T. Patel, P. M. de Luca, R. W. Lindsay, D. F. Davey, B. J. Flynn, S. T. Hoff, P. Andersen, S. G. Reed, S. L. Morris, et al. 2007. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13:843-850.
27. Hollenbaugh, J. A., J. Reome, M. Dobrzanski, and R. W. Dutton. 2004. The rate of the CD8-dependent initial reduction in tumor volume is not limited by contact-dependent perforin, Fas ligand, or TNF-mediated cytolysis. J. Immunol. 173:1738-1743.
28. Takeuchi, M., P. Alard, and J. W. Streilein. 1998. TGF-β promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol. 160:1589-1597.
29. Hu, D. E., S. O. Dyke, A. M. Moore, L. L. Thomsen, and K. M. Brindle. 2004. Tumor cell-derived nitric oxide is involved in the immune-rejection of an immunogenic murine lymphoma. Cancer Res. 64:152-161.
30. Taylor, A. W. 2007. Ocular immunosuppressive microenvironment. Chem. Immunol. Allergy 92:71-85.
31. Winn, H. J. 1961. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts. J. Immunol. 86:228-239.
32. Miki, S., B. Ksander, and J. W. Streilein. 1993. Complete elimination ('cure') of progressively growing intraocular tumors by local injection of tumor-specific CD8+ T lymphocytes. Invest. Ophthalmol. Vis. Sci. 34:3622-3634.
33. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439:682-687.
34. Wherry, E. J., S. J. Ha, S. M. Kaech, W. N. Haining, S. Sarkar, V. Kalia, S. Subramaniam, J. N. Blattman, D. L. Barber, and R. Ahmed. 2007. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27:670-684.
35. Knisely, T. L., M. W. Luckenbach, B. J. Fischer, and J. Y. Niederkorn. 1987. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J. Immunol. 138:4515-4523.
36. Taylor, A. W., D. G. Yee, and J. W. Streilein. 1998. Suppression of nitric oxide generated by inflammatory macrophages by calcitonin gene-related peptide in aqueous humor. Invest. Ophthalmol. Vis. Sci. 39:1372-1378.
37. Nicholson, B., C. K. Manner, J. Kleeman, and C. L. MacLeod. 2001. Sustained nitric oxide production in macrophages requires the arginine transporter CAT2. J. Biol. Chem. 276:15881-15885.
38. Bertholet, S., E. Tzeng, E. Felley-Bosco, and J. Mauël. 1999. Expression of the inducible NO synthase in human monocytic U937 cells allows high output nitric oxide production. J. Leukoc. Biol. 65:50-58.
39. Mori, M. 2007. Regulation of nitric oxide synthesis and apoptosis by arginase and arginine recycling. J. Nutr. 137 (6, Suppl 2) 1616S-1620S.
40. Stickings, P., S. K. Mistry, J. L. Boucher, S. M. Morris, and J. M. Cunningham. 2002. Arginase expression and modulation of IL-1beta-induced nitric oxide generation in rat and human islets of Langerhans. Nitric Oxide 7:289-296.
41. Baek, K. J., B. A. Thiel, S. Lucas, and D. J. Stuehr. 1993. Macrophage nitric oxide synthase subunits. Purification, characterization, and role of prosthetic groups and substrate in regulating their association into a dimeric enzyme. J. Biol. Chem. 268:21120-21129.
42. Faunce, D. E., K. H. Sonoda, and J. Stein-Streilein. 2001. MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol. 166:313-321.
43. Kusmartsev, S., and D. I. Gabrilovich. 2005. STAT1 signaling regulates tumorassociated macrophage-mediated T cell deletion. J. Immunol. 174:4880-4891.
44. Dolcetti, L., E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, M. Geilich, G. Winkels, E. Traggiai, A. Casati, et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40:22-35.
45. Gallina, G., L. Dolcetti, P. Serafini, C. de Santo, I. Marigo, M. P. Colombo, G. Basso, F. Brombacher, I. Borrello, P. Zanovello, et al. 2006. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116:2777-2790.
46. Sinha, P., V. K. Clements, S. K. Bunt, S. M. Albelda, and S. Ostrand-Rosenberg. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977-983.
47. Youn, J. I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:5791-5802.
48. Streilein, J. W., and J. Y. Niederkorn. 1985. Characterization of the suppressor cell (s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells. J. Immunol. 134:1381-1387.
49. Niederkorn, J. Y., and P. C. Meunier. 1985. Spontaneous immune rejection of intraocular tumors in mice. Invest. Ophthalmol. Vis. Sci. 26:877-884.
50. Schurmans, L. R., L. Diehl, A. T. den Boer, R. P. Sutmuller, Z. F. Boonman, J. P. Medema, E. I. van der Voort, J. Laman, C. J. Melief, M. J. Jager, and R. E. Toes. 2001. Rejection of intraocular tumors by CD4 (+) T cells without induction of phthisis. J. Immunol. 167:5832-5837.
51. Wang, S., Z. F. Boonman, H. C. Li, Y. He, M. J. Jager, R. E. Toes, and J. Y. Niederkorn. 2003. Role of TRAIL and IFN-gamma in CD4+ T celldependent tumor rejection in the anterior chamber of the eye. J. Immunol. 171:2789-2796.
52. Boonman, Z. F., L. R. Schurmans, N. van Rooijen, C. J. Melief, R. E. Toes, and M. J. Jager. 2006. Macrophages are vital in spontaneous intraocular tumor eradication. Invest. Ophthalmol. Vis. Sci. 47:2959-2965.
53. Dace, D. S., P. W. Chen, and J. Y. Niederkorn. 2008. CD4+ T-cell-dependent tumour rejection in an immune-privileged environment requires macrophages. Immunology 123:367-377.